Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
29 September 2015 - 1:00AM
Business Wire
Novel 10 kHz rapifleX Offers Breakthrough
TOF/TOF Performance and Robustness for Primary Structure and PTM
Determination in Proteomics, MALDI Tissuetyping and Biopharma
Applications
At the 14th Human Proteome Organization World Congress (HUPO),
Bruker today announced the new rapifleX MALDI-TOF/TOF mass
spectrometer. MALDI-TOF/TOF is established as a powerful tandem
mass spectrometry method for in-depth protein analysis. With its
redesigned, next-generation TOF/TOF ion optics, the rapifleX system
now offers significantly higher speed, mass resolution and mass
accuracy. The rapifleX integrates a novel, 10 kHz smartbeam™ 3D
scanning laser design for breakthrough mass-spec imaging
capabilities with dramatically improved spatial resolution, image
contrast and quality, and a new ion source for superior robustness
and throughput in pathology research.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150928006154/en/
New rapifleX™ MALDI-TOF/TOF (Photo:
Business Wire)
Tissue- and cell-type specific proteomics is a major advance for
relevant biomarker discovery and identification, and requires MALDI
tissue imaging studies which include the identification of detected
biomarker candidates for validation and the subsequent development
of targeted assays. The rapifleX MALDI-TOF/TOF extends the MALDI
Tissuetyper® imaging capabilities with rapid, spatially resolved
MS/MS data. It supports the patented ImageID™ workflow for
biomarker discovery in MALDI imaging cohort studies by obtaining
matching identifications of tryptic peptides in bottom-up imaging
studies.
Dr. Dietrich Hauffe, Executive Vice President for Life Science
Mass Spectrometry at Bruker Daltonics, commented: “With the
rapifleX MALDI-TOF/TOF introduction, we can now offer both, greatly
enhanced TOF/TOF performance for structural characterization, and
breakthrough MS imaging capabilities for cutting-edge proteomics
research laboratories, for biopharma customers, and for clinical
researchers in pathology. Its unparalleled speed, throughput,
structural capabilities, imaging capabilities, as well as MALDI
ease of use and robustness, make the new rapifleX MALDI-TOF/TOF a
game-changing new research and validation tool.”
About the rapifleX MALDI-TOF/TOF system
In addition to next-generation tissue imaging performance, the
rapifleX MALDI-TOF/TOF system is well suited for detailed protein
characterization in life science research and biopharmaceutical
laboratories. The rapifleX MALDI-TOF/TOF system will improve many
protein characterization tasks:
- Peptide mass fingerprints for protein
identification
- Fast identification of
post-translational modifications (PTM)
- Fast identification of impurities
- Top-down protein sequencing
- T3-Sequencing to identify or confirm
suspected modifications or sequence alterations at protein N- or
C-termini. T3-Sequencing is patented for protein terminal structure
determination.
- Fully automated Disulfide Bond analysis
of intact proteins without a priori assumptions using
DisulfideDetect™ method and software.
The rapifleX™ MALDI-TOF/TOF system is for research use only.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance instruments
and high-value analytical solutions enable scientists to explore
life and materials at molecular, cellular and microscopic
levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, Nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150928006154/en/
Investor Contact:Bruker CorporationJoshua Young, +1
978-667-9580, ext. 1479Vice President, Investor
Relationsjoshua.young@bruker.comorMedia Contact:Bruker
DaltonicsBob Galvin, +44 7881 811287Vice President, Business Unit
Omics & Biopharmabob.galvin@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024